Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 9 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Vrije Universiteit Brussel has 12 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 12 distinct examiners across 9 distinct art units, indicating that every pending action has a separate examiner and that some art units contain more than one matter.
BRYANT, REBECCA CAROLE is the busiest examiner, with 1 pending matter. Prosecution planning should emphasize consistent portfolio positions while allowing responses to reflect the different examiner and art-unit settings.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (17%) |
| §103 only | 1 (8%) |
| §112 only | 5 (42%) |
| Double-patenting + other | 2 (17%) |
| Multi-statute (no §101) | 2 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRYANT, REBECCA CAROLE | 1 | 64.8% | +32.4% |
| SINGH, AMNEET | 1 | 79.0% | +8.8% |
| STEVENS, MARK V | 1 | 65.5% | +41.6% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
| MACFARLANE, STACEY NEE | 1 | 53.7% | +39.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688085 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STEVENS, MARK V | 67d overdue |
| 18255433 | AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER | MACFARLANE, STACEY NEE | 29d |
| 19185404 | ASYNCHRONOUS TRANSIENT SIGNAL ANALYSIS | BRYANT, REBECCA CAROLE | — |
| 18516777 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | LI, RUIXIANG | — |
| 18258495 | CARDIOMYOCYTE-DERIVED NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688085 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STEVENS, MARK V | 67d overdue |
| 18269380 | IMMUNE CHECKPOINTS | BORGEEST, CHRISTINA M | 4d overdue |
| 18258102 | G PROTEIN PEPTIDOMIMETICS | BOWLES, DAVID PAUL | 4d overdue |
| 18255433 | AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER | MACFARLANE, STACEY NEE | 29d |
| 18259141 | NON-BLOCKING HUMAN CCR8 BINDERS | WANG, CHANG YU | 41d |
| 18275986 | SARBECOVIRUS BINDERS | MELCHIOR, JAMES RYLAND | 69d |
| 19185404 | ASYNCHRONOUS TRANSIENT SIGNAL ANALYSIS | BRYANT, REBECCA CAROLE | — |
| 18516777 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1675 | 3 |
| 2633 | 1 |
| 1613 | 1 |
| 1674 | 1 |
| 1644 | 1 |
| 1635 | 1 |
| 1654 | 1 |
| 1634 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19185404 | ASYNCHRONOUS TRANSIENT SIGNAL ANALYSIS | BRYANT, REBECCA CAROLE | — | §101§103§112 | Non-Final OA | — | Pending | Apr 22, 2025 |
| 18956914 | DIGITAL POLAR TRANSMITTER, METHOD FOR IMPROVING A DIGITAL POLAR TRANSMITTER, AND CORRESPONDING COMPUTER PROGRAM | SINGH, AMNEET | 2633 | §103 | Final Rejection | 28d overdue | Pending | Nov 22, 2024 |
| 18688085 | Methods for Isolation of Lipid-Disc Compositions and Uses Thereof | STEVENS, MARK V | 1613 | §101§103§112 | Final Rejection | 67d overdue | Pending | Feb 29, 2024 |
| 18516777 | Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof | LI, RUIXIANG | 1674 | §102§112Other | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18275986 | SARBECOVIRUS BINDERS | MELCHIOR, JAMES RYLAND | 1644 | §112 | Final Rejection | 69d | Pending | Aug 04, 2023 |
| 18269380 | IMMUNE CHECKPOINTS | BORGEEST, CHRISTINA M | 1675 | §112 | Final Rejection | 4d overdue | Pending | Jun 23, 2023 |
| 18259141 | NON-BLOCKING HUMAN CCR8 BINDERS | WANG, CHANG YU | 1675 | §112 | Final Rejection | 41d | Pending | Jun 23, 2023 |
| 18258495 | CARDIOMYOCYTE-DERIVED NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | SHIN, DANA H | 1635 | §112 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18258102 | G PROTEIN PEPTIDOMIMETICS | BOWLES, DAVID PAUL | 1654 | §112 | Final Rejection | 4d overdue | Pending | Jun 16, 2023 |
| 18255433 | AN LTBR AGONIST IN COMBINATION THERAPY AGAINST CANCER | MACFARLANE, STACEY NEE | 1675 | §103§112 | Final Rejection | 29d | Pending | Jun 01, 2023 |
| 17812951 | Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | — | Pending | Jul 15, 2022 |
| 17604559 | MRNA FORMULATION | HOPKINS, SAMANTHA LAKE | 1641 | §103DP | Final Rejection | — | Pending | Oct 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVrije Universiteit Brussel has 12 pending office actions as of October 2026, spread across 9 art units and 12 examiners.
Rebecca Carole Bryant has the most, with 1 of Vrije Universiteit Brussel's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
